Investment
Features
FeesSafety
Academy
More
Pluang+

Cullen/Frost Bankers shares remain pricey despite strong fundamentals; Q3 earnings on Oct 29 are key.

Analyst Insights
16 Oct 2026
Seeking Alpha
View Source
Neutral
Cullen/Frost Bankers shares remain pricey despite strong fundamentals; Q3 earnings on Oct 29 are key.

Cullen/Frost Bankers is rated as a 'hold' due to its expensive share price despite solid fundamentals like improved net interest margin, profitability, and asset quality. Management is shifting assets toward higher-yielding loans and securities, increasing leverage to boost returns. The upcoming Q3 2026 earnings report on October 29 is crucial; strong results could justify the current valuation, while weaker performance might lead to a downgrade. Investors should watch this report closely for future guidance.

Cullen/Frost Bankers stock is discussed here, with Pluang's Financials sector data providing market context. Of 142 priced Financials-sector US stocks on Pluang, 83 rose and 48 fell today. Notable movers include KB Financial Group at USD 119.93 with a 1-day change of +1.74%, Robinhood Markets at USD 102.20 with 12% sell and 88% buy order activity, and Lufax Holding at USD 0.90 with 100% sell order activity, as of Oct 16, 2026 20:11 WIB.

More News

FDA approves phentolamine eye drops for presbyopia, offering a new treatment for age-related near vision loss.

FDA approves phentolamine eye drops for presbyopia, offering a new treatment for age-related near vision loss.

Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...

Market News
Bullish
42 minutes ago
K2 Vision performs 5,000 Light Adjustable Lens procedures, leading globally in this advanced vision tech.

K2 Vision performs 5,000 Light Adjustable Lens procedures, leading globally in this advanced vision tech.

K2 Vision has completed over 5,000 procedures using the Light Adjustable Lens (LAL), making it the highest-volume practice worldwide for this technology. The LAL is unique because it can be adjusted after implantation to fine-tune vision based on the...

Market News
Bullish
42 minutes ago
BlackRock's stake in Fagron drops below 3% after share transfers, holding 2.96% voting rights as of October 2026.

BlackRock's stake in Fagron drops below 3% after share transfers, holding 2.96% voting rights as of October 2026.

BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...

Market News
Neutral
42 minutes ago
BlackRock's stake in Fagron falls below 3% after share disposals, now holding 2.96% voting rights.

BlackRock's stake in Fagron falls below 3% after share disposals, now holding 2.96% voting rights.

BlackRock, Inc. disclosed that its shareholding in Fagron NV dropped below the 3% threshold to 2.96% after selling some voting securities, despite acquiring equivalent financial instruments. As of October 12, 2026, BlackRock holds 2,015,779 voting ri...

Market News
Neutral
42 minutes ago
Meridian International Center names 25 leaders shaping U.S. global influence across sectors in 2026 cohort

Meridian International Center names 25 leaders shaping U.S. global influence across sectors in 2026 cohort

Meridian International Center announced its inaugural New Architects of American Influence cohort, recognizing 25 leaders from business, technology, culture, sports, and government who are shaping U.S. global influence. The 2026 cohort includes leade...

Market News
Bullish
49 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App